Clinical Trials

List clinical trials by disease

Search Clinical Trials

The results of your search are listed below. To view the details of a trial or study, click on the "see details >>" link. Or start a new search.

Searched for: Ovarian Cancer. 10 results shown below.

Vaccine Therapy in Treating Patients With Stage III-IV Ovarian Cancer

[Complete title: A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine Encoding the Amino Acids 1-163 of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Patients with Advanced Ovarian Cancer]
Principal Investigator: Nora Disis, MD
Study Number: 7396
Phase: I

Memory and Thinking Skills Workshop in Improving Cognitive Rehabilitation in Ovarian Cancer Survivors

[Complete title: Behavioral and Neural Indices of Cognitive Rehabilitation in Ovarian Cancer: A Pilot Study]
Principal Investigator: Heidi Gray, MD
Study Number: 7750
Phase: Pilot

A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel (CT-2103) (IND # 70177), Versus No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0212
Phase: III

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination with Bevacizumab (NSC#704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0213
Phase: II/III

A Randomized Phase III Trial of Paclitaxel plus Carboplatin versus Ifosfamide plus Paclitaxel in Chemotherapy-Naïve Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0261
Phase: III

A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC#683864, IND#61010) in Combination with Carboplatin and Paclitaxel followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
Principal Investigator: Benjamin Greer, MD
Study Number: GOG 0268
Phase: II

Study of MDX-1105 in Subjects With Selected Advanced or Recurrent Solid Tumors (MDX1105-01)

[Complete title: A Phase 1, Open label, Multicenter, Dose escalation, Multidose Study of BMS 936559 (MDX 1105) Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors (WIRB's Study#: 1107927, Protocol#: 20082100)]
Principal Investigator: Scott Tykodi, MD
Study Number: 7104
Phase: I

Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

[Complete title: Protocol EC-FV-06: A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (Pld/Doxil®/Caelyx®) In Combination Versus PLD In Participants with Platinum-Resistant Ovarian Cancer]
Principal Investigator: Barbara Ann Goff, MD
Study Number: 7334
Phase: III

MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

[Complete title: Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients with Ovarian or Breast Cancer]
Principal Investigator: Barbara Ann Goff, MD
Study Number: 7527
Phase: I/II

EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer (ESP2011-002)

[Complete title: EP-100, a Novel LHRH Receptor-Targeted Membrane-Disruptive Peptide, plus Paclitaxel® versus Paclitaxel® alone for Refractory or Recurrent Ovarian Cancer: a Phase II, Randomized, Multi-Center Trial]
Principal Investigator: Renata Urban
Study Number: 7685
Phase: I/II

Search Options

Select a disease from the list below:
Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:
Limit results to studies enrolling:

OR

View all studies
Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.